Antibiotic resistance, commonly known as antimicrobial resistance (AMR), is a global phenomenon and a well-recognised threat to public health, as well as animal health. The HPRA is actively involved in helping address the issue, as one of the actors involved in this highly-complex situation where a coordinated approach across international and species borders is needed to achieve tangible improvement.
The causal factors in the development of AMR are many and complex but originate generally from exposure of microorganisms to antibiotics. For more information, see the WHO resources on antimicrobial resistance. A particular focus is on the need to preserve the usefulness of existing antimicrobial drugs classes, as only a few new chemical classes have been developed in recent years.
Use of veterinary antibiotics
The use of antibiotics in animals is a potentially important risk factor for the selection and dissemination of resistant microorganisms and determinants from animals to humans. This risk arises via the consumption of produce (milk, eggs, honey, meat) from treated animals, but also with contact with treated animals themselves (be they pet animals or food-producing animals) as well as their environment.
Many of the antibiotics used in the treatment of animals are the same drugs as those used in human medicine, albeit that approximately 88% of veterinary drugs used in Ireland is made up by older drug classes including penicillins, tetracyclines, potentiated sulphonamides and aminoglycosides. Antibiotics have been used widely in the treatment of animals since the 1950s and are viewed by veterinary practitioners and other health care professionals as being indispensible for treating animals.
The development of resistance is a natural process which increases every time an antibiotic is used. The initial emergence of resistance is thought to be a random occurrence that arose during replication of bacteria. However, once resistance has occurred, the use of an antibiotic kills or inhibits competing bacteria present in the animal or human, thereby favouring the spread of those bacteria that have become resistant. This defensive mechanism whereby resistance genes are selected in the face of exposure to a particular antibiotic is known as selection pressure. The more often exposure occurs, the greater the risk that resistance will develop. As bacteria reproduce very rapidly, organisms with the resistant gene can rapidly become dominant in a bacterial population with an individual animal or human. Moreover, these genes appear to confer some advantages to the bacteria concerned, as they can survive in the animal, human or the environment for a long period of time, even when the use of the antibiotic has ceased for weeks or even months.
Nowadays, exposure to even one antibiotic may result in the selection of resistance to a range of other antibiotics. The reason for this is that genes conferring resistance upon bacteria are often closely linked together. During reproduction of the bacteria, these resistant genes link together and are transferred are replicated in the recipient bacteria. These genes, or DNA fragments, are available also to other bacteria that are present within the animal’s body or in the animal’s environment and may exchange genetic fragments with them. Some have likened this phenomenon to a type of ‘data cloud’, to and from which bacterial gene fragments are exchanged in a dynamic, opportunistic and promiscuous manner. Ultimately, these resistant genes are also available to bacteria which live in or on humans, which can lead to human infections in certain situations.
The problem of resistance has increased over recent decades.
The risk of resistance increases if antibiotics are used:
At too low a dosage,
For too short a duration,
As a blanket measure in an untargeted manner,
For the treatment of bacteria that are not susceptible to the particular antibiotic,
For the treatment of diseases caused by viruses or other germs not susceptible to antibiotics,
For too long a period of time.
In order for the antibiotic to be effective in the treatment of a particular disease, the drug must be delivered to the diseased tissue at a concentration which is sufficient to kill or inhibit the bacteria causing the disease, for a long enough period to allow the animal’s immune system to mount a defence. Even then, the antibiotic being used will usually inflict collateral damage on other bacteria that it encounters, be they normal inhabitants of the gut, or ultimately in the environment.
Antibiotics are powerful tools when used correctly. They are subject to prescription control in accordance with EU and national legislation. Moreover, veterinary practitioners are under ethical constraints in the manner by which antibiotics are prescribed and dispensed. Misuse of antibiotics in food-producing animals
In recent years the European Medicines Agency (EMA), acting at the request of the European Commission, has reviewed the indications and conditions under which a number of the more modern antibiotic classes (fluoroquinolones, macrolides and cephalosporins) are used in veterinary medicine. These reviews have resulted in the elaboration of more precise recommendations for use and new warnings which must be taken into account by vets when prescribing these antibiotics.
Separately, a number of organisations have developed ‘prudent use guidelines’ or ‘responsible use guidelines’. These documents are aimed at those using and supply antibiotics and encourage the proper and targeted use of antibiotics.
Advice on the prescribing and use of veterinary antimicrobials
The HPRA has published advice for vets, pharmacists, licensed merchants and farmers who prescribe, dispense or use antimicrobial drugs. It highlights the need for attention in the prescribing and use of these medicines to safeguard human and animal health against the development of antimicrobial resistance.
In addition, specific advice on the use of antimicrobial drugs in dairy cows is available.
Veterinary medicines and medicated feed - DAFM resources
On 1 December 2021, the Department of Agriculture, Food and the Marine published information on its website about the sale, manufacture, import, export, supply, distribution, advertising, control and use of veterinary medicinal products and medicated feed. Please visit Veterinary Medicines and Medicated Feed (www.gov.ie).
Use of antimicrobial drugs in Ireland
In Ireland, the Health and Safety Executive is responsible for gathering information on the consumption of antimicrobial drugs for human use annually, in accordance with a programme known as European Surveillance of Antimicrobial Consumption (ESAC).
The HPRA is the competent authority for gathering similar data nationally in respect of veterinary antimicrobial drugs, in accordance with a sister programme knows as European Surveillance of Veterinary Antimicrobial Consumption (ESVAC). Annual reports published by the HPRA and ESVAC are available to download below.
Annual HPRA reports
Reports on veterinary consumption of antimicrobial drugs for recent years can be accessed below.
Report on Sales of Veterinary Antimicrobial Drugs in Ireland during 2009
Report on Sales of Veterinary Antimicrobial Drugs in Ireland during 2010
Report on Sales of Veterinary Antimicrobial Drugs in Ireland during 2011
Report on Sales of Veterinary Antibiotics in Ireland during 2012
Report on Sales of Veterinary Antibiotics in Ireland during 2013
Report on Sales of Veterinary Antibiotics in Ireland during 2014
Report on Sales of Veterinary Antibiotics in Ireland during 2015
Report on Sales of Veterinary Antibiotics in Ireland during 2016
Report on Sales of Veterinary Antibiotics in Ireland during 2017
Report on Sales of Veterinary Antibiotics in Ireland during 2018
Report on Sales of Veterinary Antibiotics in Ireland during 2019
Report on Sales of Veterinary Antibiotics in Ireland during 2020
*Please note several of the above reports were originally published prior to our name changing to HPRA in July 2014 and therefore references the name Irish Medicines Board (IMB).
In November 2021, ESVAC published a report on the sales of veterinary antimicrobial agents in 31 European countries in 2019 and 2020. Reports from previous years can be downloaded from the ESVAC webpage.
The EU network of medicines agencies, HMA, as well as the European Medicines Agency (EMA) and the EU Commission have developed strategic plans to address the issue (see links below). These plans seek to provide for the continued availability of effective antimicrobials for use in animals whilst at the same time acting to minimise risks to animals or humans arising from their use.
Strategy on antimicrobials
HMA and EMA
European medicines agencies network strategy (refer to page 20)
A European One Health Action Plan against Antimicrobial Resistance